Leveraging real-world data (RWD) to investigate the natural history of rare cancers treated in the US community oncology setting to provide clinical context to inform future research
Active Definitive Contract Awarded Last action
- Contract number
- 75F40123C00199
- Awardee
-
Mckesson Specialty Health Pharmaceutical & Biotech Solutions LLC UEI GWZXFMRKFS27 Part of Mckesson Corporation
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $2,949,902
Award facts
- Opportunity
-
- FY23 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Solicitation · FDABAA2300123 · Posted Nov 14, 2022
- Contract value 100% obligated
- $2,949,902.00 Current and potential, with all options
- Completion date 62% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541720 Research and Development in the Social Sciences and Humanities
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Two Step
- Pricing
- Firm Fixed Price
- Place of performance
- Irving, TX 75039, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,949,902 |
About this award
The U.S. Food and Drug Administration (FDA) awarded a $2,949,902.00 firm fixed-price contract to McKesson Specialty Health Pharmaceutical & Biotech Solutions LLC to investigate the natural history of rare cancers treated in the U.S. community oncology setting. This research aims to provide clinical context to inform future regulatory science and innovation. The contract is not set aside for small businesses. McKesson Corporation, the parent company of the prime contractor, is a large healthcare services and information technology firm that has previously received numerous federal contract awards to support pharmaceutical distribution and medical supply procurement for government agencies. This contract was awarded under the FDA's Broad Agency Announcement (BAA) for research and development to advance the agency's mission of protecting and promoting public health.
Quick answers
Who was awarded contract 75F40123C00199?
75F40123C00199 was awarded to Mckesson Specialty Health Pharmaceutical & Biotech Solutions LLC by Food and Drug Administration (Department of Health and Human Services) on September 20, 2023.
How much is contract 75F40123C00199 worth?
The government has obligated $2,949,902 on 75F40123C00199.
Was contract 75F40123C00199 competed?
The extent of competition for 75F40123C00199 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award